FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Intracellular topics
Intracellular
Extracellular
Recombinant
Cancer Cells
Side Effects
Cancer Cell
Peptide Sequence
Nanoparticle
Proinflammatory
Dysfunction
Mitochondria
Mitochondrial
Transgenic
Neurotoxic
Pancreatic

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Intracellular patents



      
           
This page is updated frequently with new Intracellular-related patents. Subscribe to the Intracellular RSS feed to automatically get the update: related Intracellular RSS feeds.

Subscribe to updates on this page: Intracellular RSS RSS

Date/App# patent app List of recent Intracellular-related patents
04/10/14
20140100283
 Method to increase absorption and bioavailability of oral glutathione patent thumbnailMethod to increase absorption and bioavailability of oral glutathione
An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of s-acetyl-glutathione (sag) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of sag in a delayed release composition..
04/10/14
20140100265
 Gene delivery vehicles in the treatment of neurodegenerative diseases patent thumbnailGene delivery vehicles in the treatment of neurodegenerative diseases
Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed.
04/10/14
20140100130
 Methods and compositions for the diagnosis of ovarian cancer patent thumbnailMethods and compositions for the diagnosis of ovarian cancer
A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (clic4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers.
04/10/14
20140099654
 Real-time monitoring patent thumbnailReal-time monitoring
Provided herein are methods for the real-time monitoring of an intracellular event or response. In particular, the methods provided herein monitor the conversion of a pro-substrate to a substrate for a protein sensor as a result of an intracellular event or response..
04/10/14
20140099291
 Methods and compositions for treatment of retinal degeneration patent thumbnailMethods and compositions for treatment of retinal degeneration
Disclosed herein are methods and compositions for treating retinal degeneration, such as occurs in retinitis pigmentosa and age-related macular degeneration, using descendents of marrow adherent stem cells that have been engineered to express an exogenous notch intracellular domain.. .
04/10/14
20140097086
 Methods for production of proteins patent thumbnailMethods for production of proteins
The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies thereby facilitating rapid isolation and purification of recombinant proteins.
03/27/14
20140088159
 Enzyme and receptor modulation patent thumbnailEnzyme and receptor modulation
Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.. .
03/27/14
20140087993
 Pepducin design and use patent thumbnailPepducin design and use
Disclosed here is the rational design and use of potent and specific gpcr antagonist pepducins based on gpcr regions such as the third intracellular loop and adjacent regions.. .
03/27/14
20140087435
 Novel microbial biocatalysts that enables use of cellodextrin as biofuel patent thumbnailNovel microbial biocatalysts that enables use of cellodextrin as biofuel
The present disclosure provides genetically engineered biocatalysts which enable intracellular assimilation of cellodextrin. The genetically engineered biocatalyst co-expresses a cellodextrin phosphorylase (cdp) gene and a cellobiose phosphorylase (cbp) gene.
03/20/14
20140081073
 Neurotrophic factor production promoting device patent thumbnailNeurotrophic factor production promoting device
A device to promote the production of neurotrophic factor without transplantation of cells or injection into the affected area is provided. The device contains a high frequency electromagnetic wave generating means generating a high frequency electromagnetic wave.
03/20/14
20140080833
Intracellular kinase inhibitors
Intracellular kinase inhibitors and their therapeutic uses for patients with t cell malignancies, b cell malignancies, autoimmune disorders, and transplanted organs.. .
03/20/14
20140080766
Compositions and methods for macromolecular drug delivery
The present invention features compositions and methods for delivering a therapeutic agent to the cytoplasm of a cell. We have developed, inter alia, a system in which two or more distinct moieties—at least one therapeutic moiety and at least one potentiating moiety—selectively target and specifically bind cell surface molecules that are then internalized to an intracellular, membrane-bound compartment, such as an endosome.
03/20/14
20140080163
Luminescent probes having a phenanthridinyl antenna, and methods of use
A molecular probe for the luminescent detection of nucleotides (e.g., adenosine nucleotides) is presented. In certain embodiments, the probe can readily distinguish between the three adenosine nucleotides in buffered aqueous conditions at neutral ph, a need for the direct monitoring of enzymatic reactions converting atp to adp or amp.
03/13/14
20140073685
Method of inhibiting nonsense-mediated mrna decay
Provided are methods for treating a nad comprising administering to a patient suffering from a nad a composition comprising an eif5a inhibitor compound in an amount effective to prevent intracellular hypusination of eif5a, whereby gene expression of nmd-susceptible mrna is increased.. .
03/13/14
20140072557
Medicinal agent for suppressing malignant tumor metastasis
A medicinal agent for suppressing or preventing the metastasis of a malignant tumor, the agent comprising, as an active ingredient, at least one kind of vascular endothelial intracellular cgmp enhancer.. .
03/06/14
20140065246
Intracellular calcium modulation for cancer treatment
Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce apoptosis selectively in tumor/cancer cells while sparing normal cells.
03/06/14
20140065172
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell.
02/27/14
20140058067
Immunoconjugates with an intracellularly-cleavable linkage
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.. .
02/27/14
20140057351
Ideotypically modulated pharmacoeffectors for selective cell treatment
In a method embodiment, a method includes introducing a plurality of ideotypically modulated pharmacoeffectors (imp) into a population of cells. Each imp may include a detection domain and an activation domain.
02/27/14
20140056815
Methods to regulate polarization and enhance function of cells
Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells..
02/20/14
20140051711
Compounds that modulate intracellular calcium
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (soc) channels. Also described herein are methods of using such soc channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of soc channel activity..
02/20/14
20140051146
Method
In one aspect there is provided a method for producing a recombinant enzyme capable of hydrolysing chlorophyll or a chlorophyll derivative, comprising a step of intracellular expression of the recombinant enzyme in a eukaryotic host cell.. .
02/20/14
20140050709
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
Disclosed are compositions and methods related to rendering ineffective th1 t cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific t cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a th1 immunostimulatory/activating signal.
02/13/14
20140045874
Prevention of alcohol reaction with dietary supplements
The present invention is directed to compositions for preventing or reducing the flush and other unpleasant symptoms that sometimes accompany the consumption of alcoholic beverages, and methods for use of said compositions. The compositions comprise an agent, or combinations of various agents, such as an agent capable of increasing intracellular or intramitochondrial concentration of nad in the subject; an agent capable of increasing glutathione concentration in the subject; an anti-oxidant; alpha-lipoic acid or a precursor to alpha-lipoic acid; and/or an agent capable of increasing the level of coenzyme a in the subject; where the agent or agents are present or administered in amounts effective to prevent or reduce the alcohol reaction in a subject who has consumed one or more alcoholic beverages..
02/13/14
20140045194
Monitoring protein trafficking using beta-galactosidase reporter fragment complementation
Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of β-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking.
02/13/14
20140044741
B-type plexin antagonists and uses thereof
The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a b-type plexin which prevents the interaction of the b-type plexin with erbb-2 for use as a medicament, in particular, for treating metastasizing cancer.
02/06/14
20140038281
System for cargo delivery into the cells
The present invention relates to a system for intracellular cargo delivery, named nickfect, comprising at least one component a, which is attached covalently to cell penetrating peptide b and/or peptide or non-peptide construct c. The said delivery system nickfect relates to chemically modified new cell-penetrating peptides (cpp) non-covalently or covalently complexed with cargo for efficient cellular..
02/06/14
20140038247
Algae having intracellular lipid particles and high lipid content
A method for increasing the lipid content of algae includes combining algae and a lipid-precipitating addition in a growth-inhibitive medium, the growth-inhibitive medium being deficient in at least one nutrient that is necessary for reproductive growth of algae, thus frustrating algae reproduction, the lipid-precipitating addition selected from hydroxyl-containing compounds and amine-containing compounds. An organic acid addition may also be combined with the lipid-precipitating addition and algae in the growth-inhibitive medium, the organic acid addition including compounds containing carboxylic acid functionality.
02/06/14
20140037748
Redox responsive polymeric nanocapsules for protein delivery
The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein.
02/06/14
20140037628
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
The disclosure provides chimeric antigen receptors (cars) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
01/30/14
20140030759
Methods of intracellular conversion of single-chain proteins into their di-chain form
The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.. .
01/30/14
20140030758
Recombinant polypeptide production method
Provided is a method capable of producing a protein at a high level using a cultured animal cell, comprising culturing a cell that expresses apes (antibody production enhancing sequence) and into which a dna encoding a desired polypeptide has been introduced, thereby producing the desired polypeptide. Apes contains a nucleotide sequence related to nfkbia and has a function of decreasing the intracellular expression of nfkbia..
01/30/14
20140030317
Modulation of cell fates and activities by phthalazinediones
Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments.
01/23/14
20140024812
Engineered intracellular sialylation pathways
Methods for manipulating carbohydrate processing pathways in cells of interest are provided. Methods are directed at manipulating multiple pathways involved with the sialylation reaction by using recombinant dna technology and substrate feeding approaches to enable the production of sialylated glycoproteins in cells of interest.
01/23/14
20140024601
Chimeric immunoreceptor useful in treating human cancers
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.
01/16/14
20140018312
Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.. .
01/16/14
20140017718
Erythrocyte mechanical fragility test
A test for erythrocyte membrane mechanical fragility, involving subjection of a sample comprising red blood cells to a mechanical stress capable of causing hemolysis, and measurement of the hemolysis present after particular extent(s) of the stress. Measurement of hemolysis can be without component separation, such as by cell-counting (optical or non-optical) or by spectral differentiation between cell-free and intracellular hemoglobin.
01/16/14
20140017706
Functional enviromics method for cell culture media engineering
This invention refers to a new method for optimizing the composition of cell culture media. This new method comprises two main stages.
01/16/14
20140017327
System for targeted delivery of therapeutic agents
The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles.
01/16/14
20140017268
Composition and methods for detecting or preventing lawsonia intracellularis infections
The invention relates to vaccines for preventing lawsonia intracellularis infections and tests for the detection of the presence of l. Intracellularis antibodies in biological samples.
01/16/14
20140017169
Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
The caged cell-penetrating peptide (ccpp) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticulate pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject.
01/09/14
20140011226
Sample probes and methods for sampling intracellular material
A sample probe includes a tip including a distal end for penetrating a cellular membrane, an opening located at or proximal to the distal end, and tip microchannels extending through the tip and communicating with the opening; and a body adjoining the tip and including body microchannels, wherein at least one of the body microchannels communicates with at least one of the tip microchannels. A method for sampling intracellular material includes inserting a probe tip through a cellular membrane; aspirating intracellular material from the cell, through an opening of the tip, and into a first microchannel of the tip; flowing isolator fluid from a second microchannel of the tip into the first microchannel to form a plug of intracellular material; and aspirating the plug and the isolator fluid through the first microchannel..
01/09/14
20140010762
Imaging agents
An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hce-1 in the cells independently of the amount of hce-2 and/or hce-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hce-1 relative to the intracellular enzymes hce-2 or hce-3.. .
01/02/14
20140004577
Microorganisms for producing putrescine and method for producing putrescine using same
The present invention relates to a putrescine-producing microorganism and a method for producing putrescine using the same. To be more specific, the present invention is directed to a microorganism given the ability to produce putrescine which is generated by blocking a biosynthetic pathway from ornithine to arginine, increasing the intracellular level of glutamate, enhancing the biosynthetic pathway of ornithine from glutamate, and introducing extracellular ornithine decarboxylase; and a method for producing putrescine by using the microorganism..
01/02/14
20140004154
Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
A biologically active rna—alkali metal—dication formulation, a pharmaceutical composition containing the complexes, and methods of producing the same. The formulation is particularly useful to introduce rna and an attached cargo into cells allowing its biological intracellular activities: e.g.
01/02/14
20140004078
Immunoconjugates with an intracellularly-cleavable linkage
The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate..
01/02/14
20140004042
Targeted delivery to human diseases and disorders
The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site.
12/26/13
20130347145
Method for accumulating protein in plant cells
According to the present invention, a method for stably accumulating a target protein in plant cells or a plant body, and a transgenic plant in which protein has accumulated, are provided. The method of the present invention is a method for accumulating protein in plant cells, comprising accumulating a target protein or a protein deficient in an n-terminal region of the target protein in vacuoles of myrosin cells present in a multiple mutant, in which myrosin cells deficient in intravacuolar protein are also present in a plant body at locations other than around vascular bundles, by expressing a gene that encodes a target protein having an intracellular membrane system localization signal on the n-terminal and a vacuole localization signal on the c-terminal in the multiple mutant..
12/26/13
20130345240
Compounds that modulate intracellular calcium
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (soc) channels. Also described herein are methods of using such soc channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of soc channel activity..
12/26/13
20130345193
Compounds that modulate intracellular calcium
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (soc) channels. Also described herein are methods of using such soc channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of soc channel activity..
12/26/13
20130344545
Microbes with an improved ability to produce ornithine and method for producing ornithine using same
The present invention relates to a microorganism having an improved ornithine-producing ability, in which the biosynthetic pathway of arginine form ornithine is blocked, the intracellular glutamate level is increased, and the biosynthetic pathway of ornithine from glutamate is enhanced, and a method for producing ornithine using the microorganism.. .
12/26/13
20130344527
Compositions and methods for modification of biomolecules
The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions.
12/19/13
20130338124
Organic compounds
The present invention relates to (1- or 2- and/or 5 and/or 7-substituted)-(3-oxy)-(4h, 4-imino, 4-thioxo or 4-oxo)-pyrazolo[3,4-d]pyrimidin-6-ones, e.g., a compound of formula ii as described below, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. Of particular interest are novel compounds useful as inhibitors of phosphodiesterase 1 (pde1), e.g., in the treatment of diseases involving disorders of the dopamine d1 receptor intracellular pathway, such as parkinson's disease, depression, narcolepsy, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction..
12/19/13
20130337494
Fluorescent cytotoxic compounds specific for the cellular polyamine transport system
Cyano-substituted anthracene containing polyamines were synthesized and shown to be efficient polyamine transporter ligands. Moreover, these compounds (3 and 4) had improved fluorescence properties over previously known anthryl-polyamine conjugates, which facilitated their intracellular trafficking by confocal microscopy and fluorescence methods.
12/19/13
20130337473
Cell identification systems and methods using functionalized micropallet arrays
Cell identification systems and methods using micropallet arrays are disclosed. According to one embodiment, a cell identification strategy involves detecting the expression patterns of markers that are expressed on cells to uniquely identify different cell populations within heterogeneous mixtures of cells.
12/19/13
20130337463
Cell-based models of neurodegenerative disease
The present invention relates to a cell-based model useful for identifying molecules that modify intracellular pathways of α-synuclein and tau aggregation and degradation.. .
12/19/13
20130337075
Nanomedicines for early nerve repair
The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions to treat neuronal injury and neuronal disease via repair of damaged membrane and suppression of intracellular inflammation..
12/19/13
20130337049
Novel use of spiegelmers
The present invention relates to the use of a l-nucleic acid as intracellularly active agent.. .
12/19/13
20130337046
Methods for improved delivery of aminothiols, dimers of aminothiols, and heterodimers composed of aminothiols
The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly.. .
12/12/13
20130331353
Cell-permeable variants of trehalose and methods for the protection of living cells
A method for synthesizing variants of tre; novel tre variants; and a method for introducing tre in sufficient concentration into the intracellular environment suitable to store treated mammalian cells, treat an aggregation disease, and protect treated cells from oxygen radicals are disclosed.. .
12/12/13
20130331330
Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase
Methods of treating alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (mark).
12/05/13
20130323837
Defined systems for epithelial cell culture and use thereof
The present invention provides cell culture media formulations which support the in vitro cultivation of animal epithelial cells. The media comprise at least one fibroblast growth factor (fgf) and at least one agent that induces increased intracellular camp levels, and optionally comprise ascorbic acid.
12/05/13
20130323832
Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
The present invention is based on the discovery antigen-presenting cells (apcs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (ido). Because expression of high levels of ido is correlated with a reduced ability to stimulate t cell responses and an enhanced ability to induce immunologic tolerance, apcs having high levels of ido may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders.
12/05/13
20130323711
Apparatus and method for isolating leukocytes and tumor cells by filtration
The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell lysates from recovered cells such as leukocytes and/or circulating tumor cells without substantial dilution of a therapeutic agent such as an anticancer drug..
12/05/13
20130323303
Drug carrier and preparation method thereof
A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid.
12/05/13
20130323284
Use of mtor inhibitors to treat bacterial infection
A method for treating a mammal having an infection with an organism that persists intracellularly in a mammalian cell by inducing an autophagy defect includes administering to the mammal an effective dose of a bioavailable agent that restores autophagy function, by inhibition of the mtor pathway.. .
11/28/13
20130316957
Smoothened polypeptides and methods of use
Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a smoothened (smo) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the smo protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.
11/28/13
20130315872
Neuron-specific retrograde transport vector
(4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the n-terminal region of an extracellular domain of rabies virus glycoprotein (rv-g) and the c-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (vsv-g), a transmembrane domain of rv-g or vsv-g, and an intracellular domain of vsv-g, and the like.. .
11/21/13
20130310458
Sensors for the detection of intracellular metabolites
The present invention also relates to a method for the identification of a cell having an increased intracellular concentration of a particular metabolite, a method for the production of a cell which is genetically modified with respect to its wild type with optimized production of a particular metabolite, a cell obtained by this method, a method for the production of metabolites and a method for the preparation of a mixture.. .
11/21/13
20130309278
Methods to regulate polarization and enhance function of cells
Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells, and normally non-excitable cells in proximity to partially or wholly non-functional excitable cells..
11/14/13
20130303576
Enzyme inhibitors
Compounds of formula (i), inhibit hdac activity: wherein a, b and d independently represent ═ch— or ═n—; w is —ch═ch—or —ch2ch2—; r1 is a carboxylic acid group (—cooh), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; r2 and r3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither r2 nor r3 is hydrogen, or r2 and r3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; y is a bond, —c(═o)—, —s(═o)2—, —c(═o)o—, —c(═o)nr′—, —c(═s)—nr′, —c(═nh)nr′ or —s(═o)2nr— wherein r′ is hydrogen or optionally substituted c1-c6 alkyl; l1 is a divalent radical of formula -(alk1)m(q)n(alk2)p- wherein m, n, p, q. Alk1 and alk2 are as defined in the claims; x1 represents a bond; —c(═o); or —s(═o)2—; —nr4c(═o)—, —c(═o)nr4—, —nr4c(═o)nr5—, —nr4s(═o)2—, or —s(═o)2nr4— wherein r4 and r5 are independently hydrogen or optionally substituted c1-c6 alkyl; and z is 0 or 1..


Popular terms: [SEARCH]

Intracellular topics: Intracellular, Extracellular, Recombinant, Cancer Cells, Side Effects, Cancer Cell, Peptide Sequence, Nanoparticle, Proinflammatory, Dysfunction, Mitochondria, Mitochondrial, Transgenic, Neurotoxic, Pancreatic

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Intracellular for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intracellular with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4809

3476

0 - 1 - 71